RARITAN, New Jersey, Sept. 30 -- Johnson and Johnson issued the following news release:

* * *

- INVOKANA(R) is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD

- Approval is based on the landmark Phase 3 CREDENCE renal outcomes study - the only completed renal outcomes study of a diabetes medicine

* * *

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Submit Form Click here for more information about our products